Table 2 Clinicopathological characteristics of patients and their correlation with ErbB1/3 protein expression
From: ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
| Total | ErbB1 | p | ErbB3 | p | ErbB1 and ErbB3 | p | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Over expression | Normal | Over expression | Normal | Over expression | Normal | |||||
| Age | 96 (40–80) | |||||||||
| Sex | 0.313 | 0.485 | 0.791 | |||||||
| Male | 38 (76%) | 19 (50%) | 19 (50%) | 16 (42.1%) | 22 (57.9%) | 11 (28.9%) | 27 (71.1%) | |||
| Female | 12 (24%) | 4 (33.3%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | 3 (25%) | 9 (75%) | |||
| Size | 82 (30–100) | |||||||||
| Location | 0.730 | 0.485 | 0.797 | |||||||
| Cardia | 12 (24%) | 5 (41.7%) | 7 (58.3%) | 4 (33.3%) | 8 (66.7%) | 3 (25%) | 9 (75%) | |||
| Non-cardia | 38 (76%) | 18 (47.4%) | 20 (52.6%) | 16 (42.1%) | 22 (57.9%) | 11 (28.9%) | 27 (71.1%) | |||
| Lauren classification | 0.999 | 0.999 | 0.550 | |||||||
| Intestinal | 47 (94%) | 22 (46.8%) | 25 (53.2%) | 19 (40.4%) | 28 (59.6%) | 14 (29.8%) | 33 (70.2%) | |||
| Diffuse | 3 (6%) | 1 (33.3%) | 2 (66.7%) | 1 (33.3%) | 2 (66.7%) | – | 3 (100%) | |||
| Macroscopy | 0.028 | < 0.05 | < 0.05 | |||||||
| Infiltrative | 18 (36%) | 12 (66.7%) | 6 (33.3%) | 17 (94.4%) | 1 (5.6%) | 12 (66.7%) | 6 (33.3%) | |||
| Ulceroinfiltrative | 32 (64%) | 11 (34.4%) | 21 (65.6%) | 3 (9.4%) | 29 (90.6%) | 2 (6.2%) | 30 (93.8%) | |||
| Differentiation | 0.028 | < 0.05 | < 0.05 | |||||||
| Poorly | 20 (40%) | 13 (65%) | 7 (35%) | 19 (95%) | 1 (5%) | 13 (65%) | 7 (35%) | |||
| Not-poorly | 30 (60%) | 10 (33.3%) | 20 (66.7%) | 1 (3.3%) | 29 (96.7%) | 1 (3.3%) | 29 (96.7%) | |||
| Stage (TNM) | 0.027 | < 0.05 | < 0.05 | |||||||
| I–II | 28 (56%) | 9 (32.1%) | 19 (67.9%) | – | 28 (100%) | – | 28 (100%) | |||
| III–IV | 22 (46%) | 14 (63.6%) | 8 (36.4%) | 20 (90.9%) | 2 (9.1%) | 14 (63.8%) | 8 (36.2%) | |||
| Tumor depth of invasion | 0.999 | 0.254 | 0.550 | |||||||
| T1–T2 | 3 (6%) | 1 (33.3%) | 2 (66.7%) | – | 3 (100%) | – | 3 (100%) | |||
| T3–T4 | 47 (94%) | 22 (46.8%) | 25 (53.2%) | 20 (42.6%) | 27 (57.4%) | 14 (29.8%) | 33 (70.2%) | |||
| Lymph node metastasis | 0.493 | 0.503 | 0.999 | |||||||
| Positive | 48 (98%) | 23 (47.9%) | 25 (52.1%) | 20 (41.7%) | 28 (58.3%) | 14 (29.2%) | 34 (70.8%) | |||
| Negative | 2 (2%) | – | 2 (100%) | – | 2 (100%) | – | 2 (100%) | |||
| Recurrence | 0.013 | < 0.05 | < 0.05 | |||||||
| Positive | 21 (42%) | 14 (66.7%) | 7 (33.3%) | 20 (95.2%) | 1 (4.8%) | 14 (66.7%) | 7 (33.3%) | |||
| Negative | 29 (58%) | 9 (31%) | 20 (69%) | – | 29 (100%) | – | 29 (100%) | |||
